Jazz SVP receives 10,116 shares via performance award
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.
Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Ordinary Shares | 10,116 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents ordinary shares of the Issuer that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is the insider involved in this Jazz Pharmaceuticals (JAZZ) Form 4 filing?
What transaction did Mary Elizabeth Henderson report in this JAZZ Form 4?
Was this Jazz Pharmaceuticals (JAZZ) Form 4 transaction a market purchase?
Does this Jazz Pharmaceuticals Form 4 involve any derivative securities?
AI-generated analysis. How Rhea-AI works. Not financial advice.